New drug shows promise for Tough-to-Treat stomach cancer

NCT ID NCT06123468

Completed Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called sacituzumab-govitecan in 58 people with advanced stomach cancer that had spread to other parts of the body. The drug targets a protein on cancer cells to deliver chemotherapy directly. The goal was to see if the drug could shrink tumors or slow the disease. This was an early-phase trial to check effectiveness and safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGOGASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGOGASTRIC ADENOCARCINOMA

Contacts and locations

Show contact details

Locations

Hämatologisch-Onkologische Praxis Eppendorf

Hamburg, 20249, Germany
Klinikum rechts der Isar der TU München

München, 81675, Germany
Nationales Centrum für Tumorerkrankungen

Heidelberg, 69120, Germany
Onkopraxis Probstheida

Leipzig, 04289, Germany
SCRI-CCCIT GmbH

Salzburg, 5020, Austria
Universitätsklinikum Jena

Jena, 07747, Germany
Universitätsklinikum Leipzig

Leipzig, 04103, Germany
Universitätsklinikum Mannheim

Mannheim, 68167, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.